Fundraising FoxNGN Capital
Venture capitalNew York · Series A–Late Stage · 5 people tracked
Find your way into NGN Capital
Sign up to see every warm intro you have to NGN Capital
- Paths you didn't know you had: your email and LinkedIn already hold routes to the NGN Capital team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Investment thesis
NGN Capital is a venture capital firm dedicated to the healthcare sector, backing companies across biotech, pharmaceutical, and medical device fields. The team combines deep industry, clinical, and financial experience, drawing on backgrounds in pharmaceutical development, healthcare investment banking, corporate development, and drug and device approvals. Operating from New York and Heidelberg, Germany, the firm invests through U.S. and German funds totaling roughly $450 million.
Source: firm website, verified Sep 29, 2026.
Team · 5 people
from the firm's website & public directories
What they invest in
from 4 of 4 portfolio companiesBiotech ×4Healthtech ×3Medical Devices ×2
HQs:United States×4
Investments · 4 tracked
founders shown can be your intro pathBy year:2016 · 12009 · 23 dated
Vivaldi Biosciences develops Delta NS1 vaccines designed to protect against epidemic and pandemic viral respiratory diseases.
BiotechHealthtechMedical DevicesFort Collins, US
Peter Palese(Founder & Scientific Advisor)Adolfo García-Sastre(Founder & Scientific Advisor)Elliott Kieff(Founder & Scientific Advisor)William Wick(CEO, Board Member and Managing Director)
Co-investorsBay City Capital
Cerapedics develops P-15 peptide enhanced bone graft products, marketed as bone growth accelerators, for spinal fusion procedures.
BiotechHealthtechMedical DevicesWestminster, US
Andrew J. Tofe(Director)inBritt Pearson(Executive Officer)inJeff Marx(Executive Officer)inGlen Kashuba(Executive Officer, Director)inJerome Connor(Executive Officer)inAndrew Handwerker(Executive Officer)
Co-investorsRevelation PartnersOrbiMed
BiotechHealthtechCambridge, US
James McCullough(Executive Officer, Director)William Kelly(Chief Financial Officer and Secretary of Issuer)Thomas McLain(Chief Executive Officer and Director of Issuer)Sara Barrington(Executive Officer)
BoardJoseph Boystak(Director)inGeert-Jan Mulder(Director)in
Co-investorsArcus VenturesForbion
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.
Fund performance · per public LP disclosures · 2
as of Jun 2025| Fund | Vintage | Committed | Net IRR | TVPI | DPI |
|---|---|---|---|---|---|
| NGN BioMed Opportunity IILPs: New York City Police Pension Fund | 2008 | — | 0.6% | 1.05x | 1.05x |
| NGN BioMed Opportunity II, L.P.LPs: New York City Employees' Retirement System, Teachers' Retirement System of the City of New York, New York City Police Pension Fund +1 more | 2008 | — | 0.6% | 1.05x | 1.05x |
Source: public limited-partner disclosures (CalPERS, CalSTRS). Net IRR / TVPI / DPI as reported by the limited partner; a fund's early-year IRR is an interim estimate (J-curve).
Frequently asked questions
- What stage does NGN Capital invest at?
- NGN Capital invests at the Series A, Series B, Series C, Growth, Late Stage stages.
- What sectors does NGN Capital focus on?
- NGN Capital focuses on Biotech, Digital Health, Healthtech, Medical Devices.
- Where is NGN Capital located?
- NGN Capital is headquartered in New York, US.
Similar investors
.jpeg){kind=logo}
B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.
GV (Google Ventures) is a venture capital firm that has invested in AI and machine learning since its early days, backing more than 100 AI companies across infrastructure, life sciences, and applications.
Menlo Ventures is an early-stage venture capital firm backing transformative technology companies, with a strong current emphasis on artificial intelligence across enterprise, healthcare, and consumer markets.
Norwest is a venture capital and growth equity investment firm that has backed over 700 companies across technology, consumer, and healthcare over its 65-year history.
Sofinnova is an investment firm focused on the life sciences and biotechnology sector, partnering with companies from inception through drug development, regulatory approval, company building, and IPO.